相似文献
1
Darbepoetin alfa (Aranesp).
Proc (Bayl Univ Med Cent). 2002 Jul;15(3):332-5. doi: 10.1080/08998280.2002.11927861.
2
Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Am J Nephrol. 2006;26(2):149-56. doi: 10.1159/000092852. Epub 2006 Apr 21.
3
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
Circulation. 2011 Dec 20;124(25):2903-8. doi: 10.1161/CIRCULATIONAHA.111.030411. Epub 2011 Nov 21.
4
Purification and Characterization of Recombinant Darbepoetin Alfa from Leishmania tarentolae.
Mol Biotechnol. 2016 Sep;58(8-9):566-72. doi: 10.1007/s12033-016-9954-x.
5
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Am J Kidney Dis. 2013 Feb;61(2):238-46. doi: 10.1053/j.ajkd.2012.08.043. Epub 2012 Nov 16.
6
Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
Oncology (Williston Park). 2006 Jul;20(8 Suppl 6):29-32.
7
Darbepoetin alfa: a new therapy for the management of anaemia associated with chronic kidney disease.
Expert Opin Biol Ther. 2002 Dec;2(8):977-84. doi: 10.1517/14712598.2.8.977.
8
Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.
Expert Opin Biol Ther. 2003 Jun;3(3):501-8. doi: 10.1517/14712598.3.3.501.
9
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
J Natl Cancer Inst. 2002 Aug 21;94(16):1211-20. doi: 10.1093/jnci/94.16.1211.
10
Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa.
Nephrol Dial Transplant. 2006 May;21(5):1312-6. doi: 10.1093/ndt/gfk048. Epub 2006 Jan 5.
引用本文的文献
1
Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair.
Int J Mol Sci. 2022 Jun 27;23(13):7143. doi: 10.3390/ijms23137143.
2
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP) Biosimilar, to Those of NESP After a Single Subcutaneous or Intravenous Administration to Healthy Subjects.
Drug Des Devel Ther. 2021 Apr 28;15:1735-1747. doi: 10.2147/DDDT.S303772. eCollection 2021.
3
Deimmunization of protein therapeutics - Recent advances in experimental and computational epitope prediction and deletion.
Comput Struct Biotechnol J. 2020 Dec 29;19:315-329. doi: 10.1016/j.csbj.2020.12.024. eCollection 2021.
4
Guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2014.
Rev Bras Hematol Hemoter. 2014 Nov-Dec;36(6):450-3. doi: 10.1016/j.bjhh.2014.09.009. Epub 2014 Oct 1.
5
Recent developments in protein and peptide parenteral delivery approaches.
Ther Deliv. 2014 Mar;5(3):337-65. doi: 10.4155/tde.14.5.
6
Erythropoietin use and abuse.
Indian J Endocrinol Metab. 2012 Mar;16(2):220-7. doi: 10.4103/2230-8210.93739.
7
Cytokine combination therapy with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction.
Cardiovasc Drugs Ther. 2010 Dec;24(5-6):409-20. doi: 10.1007/s10557-010-6263-7.
本文引用的文献
1
Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.
Kidney Int. 2001 Aug;60(2):741-7. doi: 10.1046/j.1523-1755.2001.060002741.x.
2
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):24-30. doi: 10.1054/bjoc.2001.1749.
3
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):17-23. doi: 10.1054/bjoc.2001.1748.
4
Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):11-6. doi: 10.1054/bjoc.2001.1747.
5
Development and characterization of novel erythropoiesis stimulating protein (NESP).
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):3-10. doi: 10.1054/bjoc.2001.1746.
6
IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.
Am J Kidney Dis. 2001 Jan;37(1 Suppl 1):S182-238. doi: 10.1016/s0272-6386(01)70008-x.
7
Novel erythropoiesis stimulating protein.
Semin Nephrol. 2000 Jul;20(4):375-81.
8
Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.
J Am Soc Nephrol. 1999 Nov;10(11):2392-5. doi: 10.1681/ASN.V10112392.
9
Chemotherapy-induced anemia in adults: incidence and treatment.
J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34. doi: 10.1093/jnci/91.19.1616.
10
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance?
Am J Kidney Dis. 1996 Oct;28(4):535-40. doi: 10.1016/s0272-6386(96)90464-3.
Zotero 插件